arrow
D

David Foureau

wake forest comprehensive cancer center
H指数:18
被引数:2,104

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma

Belantamab mafodotin、carfilzomib、lenalidomide和dexamethasone用于复发或难治性多发性骨髓瘤

2026-02-240
OAAI
Comparative performance of the EXENT® System and electrophoretic methods for the identification and quantification of M proteins in patients with monoclonal gammopathies

EXENT®系统与电泳方法在单克隆丙种球蛋白病患者M蛋白的识别和定量中的比较性能

2025-10-010
OAAI
Diagnostic performance of the EXENT® System in monoclonal gammopathy

EXENT®系统在单克隆丙种球蛋白病中的诊断性能

2025-10-010
OAAI
Accurate recognition and characterization of biclonal gammopathies by mass spectrometry
2025-10-010
PRE
Plasma Proteomic Profiles Among White and African American Individuals With Monoclonal Gammopathy of Unknown Significance (MGUS) and Multiple Myeloma (MM)

血浆蛋白质组学特征:白人与非裔美国人中意义未明单克隆丙种球蛋白血症(MGUS)和多发性骨髓瘤(MM)患者的比较

2025-06-140
PRE
TP53 upregulation via aurora kinase inhibition overcomes primary failure to venetoclax in BCL2-rearranged lymphomas

通过抑制Aurora激酶上调TP53,克服了BCL2重排淋巴瘤对Venetoclax的原发耐药。

2025-06-010
OAAI
Nivolumab As an Adjunctive Therapy in Relapsed Refractory Multiple Myeloma Patients with Sub-Optimal Response to Idecabtagene Vicleucel

纳武利尤单抗作为伊达木单抗偶联物治疗疗效欠佳的复发难治性多发性骨髓瘤患者的辅助治疗

BLOOD
IF23.1
2024-11-050
PRE
Clonal Hematopoiesis of Indeterminate Potential Is Associated with Decreased Inflammatory Toxicity and Increased Late Cytopenia in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy

具有不确定潜力的克隆性造血与接受嵌合抗原受体T细胞疗法治疗的多发性骨髓瘤和非霍奇金淋巴瘤患者中炎症毒性的降低和晚期血细胞减少的增加相关。

BLOOD
IF23.1
2024-11-050
PRE
High-dimensional Immune Profiles and Machine Learning May Predict Acute Myeloid Leukemia Relapse Early following Transplant

高维免疫谱和机器学习可能预测移植后早期急性髓系白血病复发

2024-10-070
PRE
Impact of RAS and BRAFV600E mutations on tumor immune microenvironment and associated genomic alterations in patients with microsatellite instability (MSI) or DNA mismatch repair deficient (dMMR) colorectal cancers

RAS和 BRAFV600E 突变对微卫星不稳定(MSI)或DNA错配修复缺陷(dMMR)结直肠癌患者肿瘤免疫微环境及相关基因组改变的影响

2024-09-011
PRE
The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma
2021-10-013
OAAI